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1. Introduction 
 
1.1.  The challenges of transplantation medicine 
 
1.1.1. Transplantation tolerance 
 
In the last years, solid organ transplantation has become the therapy of choice for 
end stage kidney, liver and heart failure, and now transplantation is an established 
procedure in most university clinics. This development has been closed related to the 
fact that pharmacological immunosuppressive strategies during the last decades 
were optimized and have greatly enhanced the long-term allograft survival. However, 
most of immunosuppressive drugs non-specifically inhibit T-cell activation, clonal 
expansion or differentiation into effector cells, whereas only a fraction of the 
lymphocyte population in humans is responsible for initiating graft destruction 
(Fändrich, 2006). Generalised immunosuppression leads to numerous adverse 
effects including increased susceptibility to infections and increased risk of tumor 
development. An increase in cardiovascular diseases may also be associated with 
some conventional immunosuppressive drugs. Furthermore immunosuppressive 
drugs do not prevent chronic allograft rejection so that the long-term graft survival is 
still limited (Golshayan et al., 2007). 
 
The development of strategies that might allow the minimisation or eventual the 
cessation of conventional immunosuppression is clearly desirable. The induction of 
permanent specific tolerance to donor alloantigens is the only true solution to the 
several problems which are associated with allotransplantation (Chatenoud, 2008). 
Numerous approaches to tolerance induction in animals have shown promising 
results, but so far, no clinically practicable therapies have been established (Fändrich 
et al. 2002a; Knechtle et al., 1997). Given the favourable outcomes achieved with 
conventional immunosuppressive therapy, it is important that the inherent risks of 
trialling novel approaches to immunosuppression, including strategies to induce 
specific immunological tolerance, in transplant recipients are carefully balanced 
against the potential benefits. 
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1.1.2. The immunological basis of graft rejection 
 
Transplantation of HLA-mismatched tissues induces many changes in the host 
immune system and in the graft itself. These changes are caused, on the one hand, 
by the inevitable proinflammatory stimulation associated with surgical and ischaemic 
injury to the transplanted organ and the surrounding recipient tissue, and on the other 
hand through recognition of antigenic differences between the donor and recipient. 
These circumstances result in a powerful rejection response which inevitably leads to 
the loss of transplant if the rejection remains untreated (Dallmann et al., 1999). 
 
From an immunological standpoint, it is possible to distinguish two principal 
mechanisms of graft rejection, namely, cell-mediated and antibody-mediated immune 
responses. The latter is due to preformed antibodies which can cause a hyperacute 
rejection response resulting in an immediate failure of the transplanted organ 
following revascularization though the activation of the complement and platelets. 
Fortunately, hyperacute rejection is now a rare event because the use of 
pretransplant cross-match tests ensure that transplant recipients never receive an 
organ from a donor against whom they are sensitized (Dragun et al., 2007). 
 
The mechanisms of acute cellular graft rejection are very complex. We differentiate 
between a direct antigen response and an indirect antigen response according to the 
two different modes of antigen presentation. Rapidly after transplantation graft-
resident donor antigen-presenting cells migrate to secondary lymphoid tissues and 
encounter recipient T cells. A high proportion of recipient T cells bear a TCR that 
binds donor MHC-peptide complexes with high affinity. The allogenic MHC-peptide 
complexes provide a strong stimulus for the recipient T cells and leads to a high 
frequency of T cells which become activated to engender a direct, allospecific acute 
rejection response. Furthermore, recipient dendritic cells are capable of presenting 
graft-derived antigens in the context of self-MHC molecules which, in the surgical 
environment, provoke an indirect graft-specific T cell response. The majority of 
antigenic determinants which are recognised by responding T cells are derived from 
the variable domains of allogenic MHC Class II molecules, with fewer determinants 
derived from MHC Class I molecules and minor histocompatibility antigens 
(Golshayan et al., 2007). As many as 1/200 of recipient T cells respond to donor 
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alloantigen through the pathway of direct recognition, whereas a lesser proportion of 
recipient T cells, estimated to be 1/106 of the naive T cell pool, are activated by 
indirect recognition of donor allopeptides (Powell, 2006). Both T-cell mediated 
processes lead to acute cellular rejection. 
 
Chronic rejection is still an unresolved problem in transplantation medicine and the 
main reason for transplant failure. Chronic rejection is histologically characterized by 
inflammatory vascular injury and tissue fibrosis in the graft. These pathological 
changes are caused by T-cell mediated alloreactive responses, which trigger the 
migration of further T cells and macrophages into the graft resulting in an intermittent 
or persistent damage. Over years, a chronic transplant dysfunction develops, 
characterized by a slow loss of function (Joosten et al., 2004). So far the 
immunological basis of chronic graft rejection is still relatively unknown and, 
therefore, hardly any clinical preventive strategies exist. 
    
1.2. The mononuclear phagocyte system  
 
1.2.1. General introduction 
 
The mononuclear phagocyte system is a commonly used term which describes a 
family of cells which have their origin from bone marrow progenitors and further 
differentiate into blood monocytes and accordingly into different tissue macrophages 
and dendritic cells (Hume, 2006). Monocytes are extraordinarily versatile cell 
lineages which have the property to differentiate into diverse cell types, including 
inflammatory macrophages, various types of dentritic cells and specialised tissue 
macrophages. Macrophages exhibit great morphological variation and have diverse 
functional characteristics, directed by particular tissues and immunological 
microenvironment (Stout et al., 2004). They represent a constitutive cell population in 
most of the tissues in the human body and they play an important role in both innate 
and adaptive immunity. Diverse, often antagonistic processes are performed by 
macrophages: they participate in both tissue-destructive and reparative processes, 
and macrophages exert immunogenic and immunosuppressive functions (Gordon et 
al., 2005).  
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1.2.2. The role of the mononuclear phagocyte system in innate and     
                      adaptive immunity 
 
Due to their wide distribution in the body and their prevalence in tissues like the 
submucosa of the bowel and the airways, macrophages represent the first line of 
defence against many pathogens. Macrophages have the ability to eliminate 
pathogens by phagocytosis or by initiating the recruitment of effector cells of the 
immune system; thus, macrophages are a cornerstone of both the innate and 
adaptive immune system. In addition, macrophages prevent the systemic 
dissemination of numerous pathogens by blood circulation contributing to the 
formation of abscesses and granulomata (Gordon, 1995; Hume, 2006). 
 
Macrophages possess several different cell-surface receptors which binding 
specifically “molecular patterns” on pathogens (Janeway et al., 2002a; Taylor et al., 
2005). These specific interactions guarantee that the “molecular patterns” of the host 
remained unaffected. The macrophage mannose receptor recognises sugar 
molecules on bacterial and viral surfaces, whereas dectin-1 binds bacterial and 
fungal β-glucan. The scavenger receptor particularly recognises negatively charged 
ligands like lipoteichoic acids, and further detects structures that are normally 
shielded by sialic acids on normal host cells. This attribute is important for the 
degradation of senescent cells. Fc-receptors and complement receptors allow 
macrophages to internalise opsonized pathogens. Finally, several receptors which 
belong to the Toll-like receptor (TLR) family are located on macrophage cell surface. 
Each receptor recognizes characteristic components of pathogenic microorganisms: 
TLR-2 recognises a wide variety of different ligands, including zymosan, 
peptidoglycan and lipoteichoic acid; TLR-4 detects mainly lipopolysaccharide (LPS); 
flagellin is recognized by TLR-5 receptor; TLR-3, TLR-8 and TLR-9 are stimulated by 
bacterial and viral nucleic acid (Janeway et al., 2002b). 
 
Binding of specific “molecular patterns” of pathogens may induce the process of 
phagocytosis by which pathogens are eliminated in phagolysosomes. . Additionally 
many other bacterial toxic agents like nitric oxide, superoxide anion and hydrogen 
peroxide, which are produced by macrophages, contribute to this process. These 
mechanisms can be sufficient to prevent an infection before it becomes established. 
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Furthermore macrophages produce toxic substances such as perforin, granzyme and 
TNF-α to kill parasites, antibody-coated cells, and neoplastic cells (Aderem et al., 
1999). 
 
The production of cytokines, chemokines and other inflammatory mediators such as 
prostaglandins, leukotrienes and platelet-activating factor (PAF) by macrophages is a 
result of the interaction between macrophages and pathogens or immunological 
cells. These substances play a role initiating the inflammation at the site of infection 
reached by complex effects like recruiting other cells, increasing vascular 
permeability and expression of adhesion molecules in endothelial cells (Janeway et 
al., 2002b).  
 
Besides their central function in the innate immunity, macrophages occupy an 
important role as professional antigen-presenting cells (APC) in the adaptive immune 
system. Antigen fragments of phagocytized pathogens are presented on the cell 
surface via MHC Class II proteins. Several co-stimulatory molecules on the 
macrophage cell surface, including CD80 and CD86, are further necessary for the 
proper activation of T cells. The binding between the T-cell receptor and the MHC-II 
protein leads to IL-1 secretion by macrophages. IL-1 binds to its receptor on T cells 
and initiates an autocrine stimulation process via IL-2 in the T cell. The result is a rise 
of a clone by proliferation of the T cell (Janeway et al., 2002b). 
 
Not only the induction of inflammation within the innate and adaptive immunity, but 
also the resolution of inflammation is among other things performed by 
macrophages. It is partly based on anti-inflammatory activities of macrophages and 
further on the clearance of apoptotic cells from the site of inflammation (Roos et al., 
2004; Serhan et al., 2007). The fact that macrophages produce several tissue-trophic 
factors and promote new blood vessel formations makes them become central cells 
in tissue repair processes (Gordon, 1995; Martin et al., 2005; Tsirogianni et al., 
2006). 
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1.2.3. The heterogeneity of monocytes and macrophages 
 
The monocyte ultimately derives from the haematopoietic stem cell in bone marrow, 
which is the precursor of the common myeloid progenitor (CMP). From these 
progenitor lineage arises the granulocyte-monocyte /monocyte- colony forming units 
(GM-CFU and M-CFU) which represent the precursor population for monoblasts. 
Monoblasts are the earliest form committed to becoming monocytes which then 
released from the bone marrow into the peripheral blood, where they circulate for a 
number of days before migrating several tissues (Hume et al., 2002; Volkman et al., 
1965). 
 
Peripheral blood monocytes are quite heterogeneous; in particular the morphology 
shows substantial variances such as differences in size, different degrees of 
granularity and varied nuclear forms (Gordon et al., 2005). In addition monocyte 
heterogeneity based on differential expression of CD14 and CD16 (FcγRIII) and even 
considerable differences in the expression of chemokine receptors exist. Accordingly, 
monocytes can be divided into two subsets: the CD14high CD16- cells, described as 
classic inflammatory monocytes, and the CD14+ CD16+ cells, which are the 
precursors of tissue macrophages and are more likely to differentiate into dendritic 
cells (Passlick et al., 1989; Randolph et al., 2002; Ziegler-Heitbrock et al., 1993). A 
further monocyte subset was detected by the expression of CD14+, CD16+ and 
CD64+ (FcγRI). It is assumed that these cells combine characteristics of monocytes 
and dendritic cells and that they command immunoregulatory properties (Grage-
Griebenow et al., 2001). 
 
When monocytes are not recruited to inflammatory lesions to become activated 
macrophages, they undergo a progression of phenotypic alterations, through which 
they can maturate into different classes of tissue-resident macrophages. The 
following macrophages belong to this subset: osteoclasts, gut mucosal 
macrophages, splenic macrophages, thymic macrophages, alveolar macrophages, 
Kupffer cells and microglia. Probably monocytes also contribute to the pool of lymph 
node-resident dendritic cells (Gordon et al., 2005). 
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Macrophages are phenotypically polarized in response to extrinsic stimuli and their 
ambient microenvironment, which leads to extremely heterogeneous populations of 
cells (Mantovani et al. 2005). For this reason a near-unlimited number of alternative 
macrophage phenotypes exist and, therefore, it is difficult to categorize them 
systematically. 
 
Mantovani has proposed a classification scheme in which macrophages are divided 
into M1-polarised macrophages, which preferentially drive Th1-type T cell responses, 
and M2-polarised macrophages, which generally participate in Th2-type T cell 
responses (Mantovani et al., 2007). M1-polarised macrophages can be produced by 
treating resting macrophages with a number of pro-inflammatory agents, including 
IFN-γ, TNFα and LPS. Depending on the exposure to different agents M1-polarised 
macrophages represent a phenotypically and functionally distinct cell population, but 
these cells bear greater similarity to one another than to M2-polarised macrophages. 
The M2-polarised macrophages can be further subclassified into M2a, M2b and M2c 
macrophages (Mantovani et al., 2004). M2a macrophages, also known as 
alternatively-activated macrophages, emerge from resting macrophages stimulated 
with IL-4 or IL-13, or the combination of both (Goerdt et al., 1999; Gordon, 2003). 
M2b macrophages are generated by stimulation with immune-complexes (Mosser, 
2003; Sironi et al., 2006; Sutterwala et al. 1998). Many alternative ways producing 
M2c macrophages exist, including treatment with vitamin D derivatives, IL-10, 
dexamethasone or other corticosteroids (Barclay et al., 2002; Bhavsar et al., 2008; 
Bogdan et al., 1991; Copland et al., 2007; Joyce et al., 1997; Lang et al., 2002; 
Ogawa et al., 2006). Classifying macrophages in this way illustrates a somewhat 
artificial concept which not really reflects the extreme heterogeneity and plasticity of 
macrophages. Therefore, the polarised macrophage subsets should be considered 
as steady-state conditions within a wide spectrum of possible macrophage 
phenotypes. 
 
1.3. Generalities of cell-based therapies 
 
Exploiting the potential tolerance-inducing effects of cells like regulatory T cells and 
antigen presenting cells with T cell-suppressive properties, by transferring those cells 
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from donor to recipient is becoming an interesting possibility in transplant medicine 
(Becker et al., 2006; Fändrich, 2006). 
 
It is quite evident that cell-based therapies like these are associated with a number of 
technical and clinical problems. The respective complications obviously depends on 
the exact nature of the cells used, their way of administration and the clinical 
condition of the patient; but also possible risks like malignancy, atypical infections, 
embolism of cellular aggregates, anaphylactic reactions, sensitisation, consequences 
of massive cell lysis and graft-versus-host type disease must be considered 
(Hutchinson et al., 2008b). 
 
Since the identification and characterisation of cells with immunosuppressive or even 
tolerogenic features, great interest has developed in the possibility of inducing and 
expanding these cells types in culture before giving them to patients (Bluestone et 
al., 2007; Lechler et al., 2005; St Clair et al., 2007; Thomson et al., 2006). These 
methods might exploit cellular mechanisms which underlie other tolerance-inducing 
strategies, but ex vivo manipulation of cells opens the possibility of purification, 
expansion and quality control testing which might lead to more consistent therapeutic 
effects. If such ex vivo expansion of tolerance-inducing cells should become a 
clinically practicable strategy for immunosuppression, it is obligatory that the 
substrate cells are easily preservable from donor or recipient, that these cells should 
be subjected to the least possible manipulation to minimise the rate of technical 
failure and cost and further that the therapeutic cells should be readily and effectively 
transferred into patients.  
 
1.4. History of the Transplant Acceptance-Inducing Cell 
 
Interest in Transplant Acceptance-Inducing Cells originated from studies in which rat 
embryonic stem-cell (ESC) lines were shown to indefinitely prolong the survival of 
ectopic cardiac allografts in rats (Fändrich et al., 2002a; Inoue et al., 2006). The 
ESCs had their origin from WKY strain animals and were transferred pre-operatively 
to recipient DA rats [see figure 1.1.]. This tolerogenic effect was alloantigen-specific 
and depended on engraftment of the progeny of the transferred ESCs in the recipient 
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animal. Further investigations showed that the infused ESCs gave rise to a rather 
limited, but stable, state of chimerism and that their principal derivatives were of the 
myelomonocytic lineage (Fändrich et al., 2002a+b).   
 
 
 
Figure 1.1. Rat embryonic stem-cells prolong the survival of cardiac allografts. 
Original experiments of Fändrich et al., (2002a) demonstrated that infusion of donor 
embryonic stem-cells prior to heart transplantation improve graft survival. Figure 
adapted from Riquelme (2008). 
 
It was shown in these studies that the administration of rat ESCs did not sensitize the 
recipient animals and additionally a long-lived population of donor-derived cells 
established in the recipients providing a permanent antigenic stimulus. Brent et al. 
proposed that exactly such conditions are necessary for the induction and 
maintenance of peripheral transplantation tolerance (Brent et al., 1976). The fact that 
treatment with ESCs is not an accepted clinical practicable therapy so far; further 
studies focused their interest to identify and characterize the developed long-lived 
population of the ESCs. The phenotype of the ESC derived- cells determined them 
as a subtype of macrophages. Subsequently it was shown that equivalent cell types 
could produced from mononuclear splenocytes and blood and bone marrow 
mononuclear cells by ex vivo manipulation (Brem-Exner et al., 2008; Heumann et al., 
2005; Hutchinson et al. 2008a+b). Several animal experiments demonstrated the 
tolerogenic potential of these cells. 
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Similar methods as used in animal experiments lead to the generation of TAIC cells 
from human monocytes; a characterisation of human TAIC cells was recently 
described by Hutchinson et al. (Hutchinson et al., 2008b). Both in humans and in 
animals, TAIC cells constitute a heterogeneous mixture of quite different macrophage 
phenotypes which are contaminated with lymphocytes when they are prepared by 
conventional isolation methods. Special isolation techniques were established in 
order to achieve a more homogenous cell suspension and hence to isolate the 
effector macrophage or macrophages. Therefore the purest possible starting 
monocyte population was isolated by magnetic bead sorting and then cultured under 
TAIC-generating conditions until they achieved a steady-state phenotype. This 
procedure leads to the isolation of a relatively homogenous macrophage population 
with a characteristic phenotype. Given that these macrophages are able to promote 
regulatory T cell responses and according to Mantovani`s convention, these cells 
were named regulatory macrophages (M regs) (Hutchinson et al., 2008b). 
 
1.5. Characterisation of human M regs 
 
The regulatory macrophage represents the ultimate effector cell in the 
heterogeneous mixture of TAIC cells. The morphology is strikingly different to that of 
other macrophage subtypes and even the constellation of cell-surface markers 
shows differences ( Hutchinson J.A., unpublished data). 
 
Plated at an appropriate density of 1-2x106 monocytes per cm2 in cell culture plastic, 
M regs adopt a distinctive phenotype, which is characterised by a tessalating, 
epithelioid morphology with a prominent central body [see figure 1.2.]. Although 
binucleate forms can be seen occasionally, usually a single clear nucleus is visible 
surrounded by a thin skirt of cytoplasm. Further remarkable is the extreme granularity 
in M regs which probably is associated with their ability for phagocytosis of cellular 
debris. The size of M regs, which ranges to 50μm in diameter, constitute the most 
conspicuously morphological feature and is close related to the local cell density 
(Brem-Exner et al., 2008; Hutchinson et al., 2008b). M reg-like forms are sometimes 
detectable in cultures of other macrophages; it is assumed that the starting 
population of human peripheral blood monocytes already contained a subset of 
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monocytes that had been appropriately stimulated to become M regs. In contrast, 
pure M reg cultures contain almost exclusively cells which exhibit the typical 
morphological features described above (Hutchinson J.A., unpublished data). 
 
The cell surface phenotype overlaps in some features with known macrophage types, 
nevertheless there exist clear differences. M regs express the myeloid markers CD13 
and CD33, further the expression of CD205 identified them as cells of monocytic 
origin. During cell cultures M regs down-regulate CD14 expression which distinguish 
them from nearly all other macrophage subtypes. Further the absence of TLR2 and 
TLR4 and alike the lack of CD16 and CD163 differentiates M regs from other 
macrophages (Hutchinson et al., 2008b).  
 
M regs are predominantly CD80 negative and they appear to express lower levels of 
CD86 and HLA-DR than classically-activated macrophages, but higher levels than 
resting macrophages. That fact identifies M regs as partially-matured and relatively 
inactivated macrophage subtype which is a hallmark of tolerogenic DC populations 
(Brem-Exner et al., 2008; Reis e Sousa, 2006).     
 
 
Figure 1.2. Morphology of human M regs derived from peripheral blood 
monocytes after CD14 purification. Isolated monocytes were cultured in 10% 
HABS macrophage medium (A) supplemented with ATRA (all-trans-retinoic acid) (B) 
for seven days. On day 6 IFN-γ was given to the culture medium. Original 
magnification 500x. 
 
  
A 
 
B 
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1.6. Characterisation of the mouse TAIC  
 
Brem Exner et al. recently described the phenotypic and functional characteristics of 
IFN-γ stimulated monocyte-derived cells (IFN-γ-MdCs) in mice. Except for little 
differences in the culture medium the generation of those cells is similar to the 
generation of human TAIC cells. On the basis of their cell surface phenotype which 
mainly accords to that of TAIC cells, it is assumed that IFN-γ MdCs exist in a state of 
partial maturation (Brem-Exner et al., 2008). 
 
Numerous experiments were undertaken to demonstrate their potential tolerogenic 
effect. In a first trial IFN-γ MdCs were co-cultured with lymphocytes from mesenteric 
lymphocytes of mice suffering from DSS-induced colitis. It was observed that the 
number of lymphocytes clearly decreased over the time in the co-culture. This effect 
was also seen in lymphocytes which derived from healthy mice. Further, it was 
demonstrated that the addition of the T cell activation inhibitor cyclosporine to the co-
culture resulted in unchanged lymphocyte numbers. In contrast, lymphocytes 
stimulated with the lectine concavalin A were considerable more readily deleted by 
IFN-γ-MdCs. Therefore it was assumed that IFN-γ-MdCs preferentially eliminate 
activated T cells without consideration of their antigenic specificity (Brem-Exner et al., 
2008).     
 
The killing effect of IFN-γ-MdCs to T cells was specified in more detail. It was shown 
that the elimination of T cells is a clear cell-contact and caspase dependent process. 
Unfortunately the detailed mechanism for IFN-γ-MdCs-induced T cell death was not 
ascertained. Interestingly the IDO-mediated tryptophan depletion, which was 
responsible for induced T cell apoptosis in experiments with IFN-γ and sCD40L-
induced macrophages performed by Munn and colleagues, was not relevant for the 
induction of T cell death (Brem-Exner et al., 2008; Munn et al., 1999; Munn et al., 
1996). 
 
In the course of the co-culture experiments a proportion of residual T cells survived. 
These cells were characterized as CD4+CD25high T cells which also shown a 
relatively high expression of Foxp3 and IL-10 mRNA. The functional features of the 
CD4+CD25high cell subset also confirmed the assumption that they represent a 
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population of regulatory T cells. During the co-culture process a true enrichment of 
regulatory cells was observed indicating that IFN-γ-MdCs are capable to expand T 
cells with regulatory phenotype and properties. This effect was strictly depended to 
the presence of CD4+ cells during IFN-γ-MdCs generation. In comparison, an 
expansion of CD4+CD25high cells was not observed in resting or M1 macrophage co-
cultures (Brem-Exner et al., 2008). 
 
A mouse colitis model was established in order to analyze the therapeutic potential of 
IFN-γ-MdCs. Initially, it was demonstrated with fluorescently-labelled IFN-γ-MdCs, 
that these cells are able to migrate to the inflamed intestinal tissue and accordingly 
get in contact with disease-causing T cells. On the basis of the promising in vitro 
experiments mice suffering from DSS-induced colitis received an administration of 
5x106 IFN-γ-MdCs. This treatment led to a significant reduction of colonic 
inflammation and according to this to a gain of body weight compared with an 
untreated control group. In a further experiment, healthy BALB/c mice were treated 
with DSS to induce chronic colitis. Directly after the last treatment with DSS, mice 
received either 5x106 control cells, 5x106 IFN-γ-MdCs or left untreated. Three weeks 
later the colon tissue was histologically analyzed with the result that the majority of 
the IFN-γ-MdCs treated animals showed low-to-intermediate grades of colitis and 
even almost histological resolution of colitis was observed in some mice. In contrast, 
the control groups showed predominately severe grades of chronic colitis (Brem-
Exner et al., 2008). 
 
1.7. Animal studies with TAIC cells 
 
Several animal experiments with rats in the past demonstrated the tolerogenic 
potential of the TAIC cell, including a renal transplant model in which Lewis rats 
received grafts from DA strain animals. During this study it was revealed that non-
immunosuppressed graft recipients succumbed to renal failure after 9.0±3.0 days. 
Rats which received an intravenous infusion of donor-specific TAIC cells seven days 
before transplantation survived for more than 100 days [see figure 1.3. A]. Both 
clinical data, in term of creatinine, potassium and urea levels, and the histological 
results did not significantly differ from a control group which received syngenic 
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organs. The graft biopsies did not shown any signs of acute or chronic rejections 
(Fändrich F., unpublished data). 
 
The majority of transplants in Germany derive from deceased donors, so immune-
conditioning strategies that rely on the pre-operative transfer of donor-derived cells to 
the recipients are obviously clinical impractical (Oosterlee et al., 2008). To identify 
whether post-operative administration of TAIC cells also result in prolonged graft 
function, Inoue et al. performed experiments in which BALB /c mice achieved TAIC 
cells five days after a heterotopic heart transplantation from C3H mice. It was shown 
that the untreated control group lost their transplant because of acute rejection after 
8.5±0.8 days [see figure 1.3. B]. BALB/c mice which received 5x106 TAIC cells of 
donor origin five days after transplantation showed a significantly prolonged graft 
survival to 21.4±8.3 days (p<0.05). The administration of recipient TAIC cells 
(BALB/c) demonstrated also a marginally lengthened graft survival to 12.4±3.4 days 
(p<0.05). The treatment with MACS-sorted monocytes from both C3H and BALB/c 
mice did not result in a significantly elongation of graft survival. This observation 
proves that the graft-protective effect was TAIC cell-dependent. TAIC cells of third-
party origin (C57BL/6) did not attain an effect concerning the survival of heart 
transplants in BALB/c mice (8.8±0.8 days) (Inoue et al., 2006). 
 
 
Figure 1.3. Pre-operative (figure A) and post-operative administration (figure B) 
of TAIC cells results in transplant survival prolongation in non-
immunosuppressed animal models. Original experiments of Fändrich et al. (figure 
A) showed that an infusion of donor-specific TAIC cells prior to kidney 
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transplantations in rats considerably prolongs graft survival. Experiments performed 
by Inoue et al. (2006) (figure B) demonstrated that postoperatively given TAIC cells 
are capable of prolonging heterotopic heart transplants between C3H and BALB/c 
mice.  
 
1.8. Clinical studies with human TAIC cells 
 
The promising results in animal trials with TAIC cells and the detection of equivalent 
cell types in humans lead to the decision to trial TAIC cells as an immune-
conditioning therapy in patients receiving kidney transplants from deceased donors. 
A phase 1 clinical trail, called the TAIC-1 study, commenced in 2003 (Hutchinson et 
al., 2008b). In this study 12 recipients of renal transplants from deceased donors 
received donor TAIC cells on the fifth day postoperatively. Four weeks after 
transplantation patients were gradually weaned from conventional 
immunosuppression over a time period of eight weeks. 
 
During the first month, all participants of the TAIC-1 study were treated with 
conventional immunosuppressive triple therapy, including tacrolimus, sirolimus and 
steroids in the form of prednisolone and methylprednisolone. Initially patients were 
weaned from steroids over 14 days in week 5 and 6 postoperatively. If graft function 
remained stable at the end of the sixth week, sirolimus was also reduced namely in 
week 7 and 8. Then transplant recipients were slowly weaned from tacrolimus over a 
time-period of four weeks (weeks 9-12) up to plasma levels of 8-10 ng/ml, provided 
that the Clcr
 did not show a significant reduction (>25%) in relation to the value on day 
28 after transplantation. Further reduction was undertaken in three patients who 
presented no signs of rejection or graft dysfunction. 
 
For the TAIC-1 study, TAIC cells were generated from donor splenic mononuclear 
cells under GMP conditions. To minimize the risk of sensitising the patients against 
donor antigens, and for practical reasons, TAIC cells were administered five days 
after transplantation by central venous infusion. A number of >1x106 viable TAIC cells 
per kg bodyweight were infused.   
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The TAIC-1 study demonstrated that clinical-grade TAIC preparations could be 
reliably produced under GMP conditions and administered to patients postoperatively 
without complications. Notably, of the twelve patients enrolled in the trial, three were 
successfully weaned to tacrolimus monotherapy with trough serum tacrolimus levels 
of less than 4 ng/ml. However, four patients developed acute rejection episodes 
during the withdrawal of immunosuppression. Four further patients showed an acute 
increase in creatinine levels without any histological signs of rejection. In all eight 
cases conventional immunosuppressive regime was reintroduced and normal graft 
function was reconstituted.  
 
It is obvious that because of the limited number of study participants and the lack of a 
control arm, it is not possible to obtain clear information about a potential beneficial 
effect of TAIC cells. Though it was demonstrated that the infusion of TAIC cells did 
not lead to a sensitization of the trial recipients to donor alloantigens and also 
evidence of potential acute adverse effects like embolism, transfusion reaction and 
graft versus host disease were not observed (Hutchinson et al., 2008b).   
 
In a second clinical trial, the TAIC-2 study, TAIC cells were used as an immune-
conditioning therapy in living-donor kidney transplantation (Hutchinson et al., 2008a). 
A number of five patients received TAIC cells five days before transplantation 
appointment. This was enabled by the fact that TAIC cells were generated from a 
leucapherisis product taken from the donor. 
 
The administration of TAIC cells occurred without immunosuppression by a central 
venous catheter. After transplantation patients received anti-thymocyte globulin for 
the first three days. Additionally graft recipients were immunosuppressed with 
steroids and tacrolimus for the first eight weeks. During the eighth and tenth week 
postoperatively steroids were continuously reduced under strict monitoring for indices 
of rejection. Directly after cessation of steroids, tacrolimus was slowly reduced and 
even completely withdrawn, assuming that no signs for rejections were detectable. 
Through the RISET (Reprogramming the Immune System for the Induction of 
Tolerance) collaborative network, it was possible to monitor the TAIC-2 participants 
for various special indices of tolerance induction among other things through mixed 
lymphocyte cultures with multiple cytokine assays. 
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Under these conditions three patients tolerated low-dose tacrolimus monotherapy    
(< 4ng/ml) and another patient was completely withdrawn from immunosuppressive 
therapy for over eight months. However, one of these patient developed an acute 
rejection episode after reduction of tacrolimus trough serum levels to < 4ng/ml. 
Further two patients underwent acute rejection after complete cessation of 
immunosuppressive therapy. In all cases reintroduction of immunosuppression drugs 
lead to restoring of normal graft function. 
 
Based on these results it is possible to say that TAIC treatment, as it was used in this 
study, is not capable of inducing complete operational tolerance in renal allografts. 
Anyhow it is amazing that the reduction of immunosuppressive therapy to such small 
doses was mostly well tolerated and that in three cases the maintenance of 
tacrolimus monotherapy was sufficient to prevent allograft rejection. It is assumed 
that TAIC cells might induce a state of donor-specific hypo-responsiveness in the 
recipient. While a complete cessation of immunosuppression is not tolerated, small 
doses are sufficient to maintain adequate immunosuppression. In addition this 
suggestion was confirmed in various mixed lymphocyte cultures in which an anti-
donor T cell response was not detectable (Hutchinson et al., 2008a).      
 
1.9. Objectives 
 
There is still missing the knowledge about the concrete immunological effect of 
human TAIC cells and even long-term adverse effects so far are not excluded.       
The general objective of this thesis is the analysis of the influence of human TAIC 
cells to allogenic lymphocytes in co-culture. The main focus is fixed on a potential 
suppressive effect induced by TAIC cells. A case study, within an almost five year 
time period after the clinical application of TAIC cells as an adjunct 
immunosuppressive therapy in renal transplantation is described. Additionally a 
source of high quality leucocytes is presented which is very useful for the generation 
of experimental grade TAIC cells. 
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The specific objectives of the thesis are: 
 
1. For experimental purposes, are leucocytes obtained from leucocyte 
reduction systems of Baxter GambroTM leucapheresis machines an 
equivalent or even better alternative for leucocytes from buffy coats for use 
in Immunological experiments? 
2. Do human TAIC cells suppress T cell activation and proliferation, or even kill 
allogeneic lymphocytes? 
3. Is the administration of TAIC cells a clinical feasible immunosuppressive 
therapy?      
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2. Materials and methods 
 
2.1. Cell culture 
 
2.1.1. Blood donors 
 
Cells of human origin for experimental cell cultures were isolated from buffy coats or 
from cells obtained from the leukoreduction system chambers of apheresis 
instruments after platelet collection. Human cells were used as early as possible after 
their production, mainly between 6-12 hours after isolation, to keep the cell-quality 
high. 
 
Both buffy coats and cells from leukoreduction system chambers of apheresis 
instruments derived from the Department of Transfusion Medicine of the University 
Clinic Schleswig-Holstein, so it was guaranteed that the cells stemmed from healthy 
donors. All blood donors gave their written informed consent to the use of their cells 
for research purposes. Blood type, age and gender of the donors were established.  
 
2.1.2. Cell isolation 
 
Peripheral blood monocytes were isolated from buffy coats or leukoreduction system 
chambers by density gradient centrifugation. Therefore cells from both sources were 
transferred into three 50 ml centrifugation tubes (Becton Dickinson, Germany) and 
each tube was filled up with DPBS without Ca2+ and Mg2+ (Dulbecco´s phosphate 
buffered saline, Cambrex Bio Science, Belgium) to a volume of 50 ml. Shortly after 
that six centrifugation tubes were filled with 20 ml of Ficoll (Biochrom AG, Germany). 
Each Ficoll-tube was overlayed with 25 ml of cell-suspension. After that the resulting 
density gradients were centrifuged at 2000 rpm for 20 min at 20°C without brake. 
After centrifugation the leucocyte interfaces were collected by pipetting and were 
transferred into two new 50 ml centrifugation tubes. Then DPBS were added to the 
tubes up to a volume of 50 ml and the resulting suspension was centrifuged at 1600 
rpm for 10 min at 20°C with brake. The supernatant was carefully collected, in order 
to lose as few cells as possible, and discarded. The cell pellet on the bottom of the 
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tube was resuspended in 50 ml of DPBS and thereupon the cells were washed twice, 
centrifuging at 1000 rpm for 10 min at 20°C to remove platelets. Subsequently the 
pellet was resuspended in DPBS or medium and the number of cells was defined in 
an automatic cell counter. 
 
2.1.3. Cell medium 
 
TAIC culture medium: RPMI 1640 (BE12-918F, Cambrex Bio Science), 25mM 
HEPES (R&D Systems GmbH; Wiesbaden), 10% human AB serum (Cambrex Bio 
Science), 2mM glutamine (Gibco-Invitrogen GmbH; Karlsruhe), 100U/ml penicillin - 
100μg/ml streptomycin (Gibco-Invitrogen), 5ng/ml human M-CSF (R&D Systems). 
 
10% HABS macrophage medium: RPMI 1640 with phenol red (Cambrex Bio 
Science), 10% human AB serum (Cambrex Bio Science), 2mM glutamax (Gibco-
Invitrogen), 100U/ml penicillin - 100μg/ml streptomycin (Gibco-Invitrogen), 5ng/ml 
human M-CSF (R&D Systems). 
 
AB-Medium: RPMI 1640 with phenol red (Cambrex Bio Science), 10% human AB 
serum (Cambrex Bio Science), 2mM glutamine (Gibco-Invitrogen), 100U/ml penicillin 
- 100μg/ml streptomycin (Gibco-Invitrogen). 
 
2.1.4. Generation of TAIC cells for experimental purposes 
 
Peripheral blood monocytes were suspended in TAIC medium and plated at a 
density of 5x107 cells/cm2 in six-well plates or in T175 flasks (Sarstedt, Germany). 
The cell cultures went into the incubator overnight at 37°C and 5% CO2. On the 
following day the non-adherent cells in the supernatant were discarded and fresh 
medium was added to the adherent cell fraction in the original flasks. The flasks were 
incubated for further two days before they were treated with IFN-γ (R&D Systems) on 
day 4 at a concentration of 25 ng/ml for 24 hours. After the stimulation with IFN-γ the 
cells were ready to harvest. 
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2.1.5. Generation of M regs for experimental purposes 
 
To produce M regs, positive selected CD14+ monocytes were isolated from prepared 
buffy coats or leukoreduction system chambers with the MACS magnetic bead 
selection system (Miltenyi Biotec; Bergisch Gladbach, Germany) according to the 
manufacture’s instruction. The purified monocytes were seeded at 105 cells/cm2 in 
10% HABS macrophage medium and incubated at 37°C and 5% CO2. On day 6 the 
cells were stimulated with IFN-γ (R&D Systems) at a concentration of 25 ng/ml for 24 
hours.    
 
2.1.6. Cell Harvest 
 
Because of the fact that monocytes and macrophages adhere strongly to tissue 
culture plastic, TAIC cells were harvested by scraping with a standard rubber cell 
scraper (Sarstedt). Before scraping process, the medium of the TAIC cells were 
removed and the adherent cells were gently washed with DPBS without Ca2+ and 
Mg2+ (Cambrex Bioscience). Then chilled TAIC-medium was added to the flask and 
cells rested in the medium for 10 minutes. TAIC cells were lifted with small, gentle 
strokes by a cell scraper. The resulting cell suspension was transferred into 
centrifuge tubes (Becton Dickinson), which were put into the centrifuge for five 
minutes at 1600 rpm. 
 
2.2. Flow cytometry 
 
2.2.1. CFSE staining of responder lymphocytes 
 
For the flow cytometry-based T-cell proliferation assays the responder lymphocytes 
were labelled with the long term fluorescence CFSE (Gibco-Invitrogen). The use of 
CFSE labelled lymphocytes allows it to discriminate between responder lymphocytes, 
which were co-cultured with TAIC cells, and contaminating lymphocytes from the 
TAIC generation phase. 
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Shortly after the isolation of lymphocytes from buffy coats or leukoreduction system 
chambers a number of 250x106 leucocytes was suspended in 10ml of DPBS without 
Ca2+ and Mg2+ (Cambrex Bioscience) in a 50ml centrifugation tube (Becton 
Dickinson). In parallel 10 μl of CFSE was diluted in 10ml of DPBS in another tube. 
Subsequently both volumes were pooled and stirred extensively before the 
suspension went for 7 minutes in a 37°C warm water bath. Then the labelling-
process was interrupted with 10ml of FCS (Biochrom AG). Further the labelled 
lymphocytes were centrifuged for 10 minutes by 1600 rpm at room temperature with 
brake. Two more washes in DPBS followed, both for 6 minutes by 1000rpm. Finally 
the cells were suspended in AB-medium and incubated overnight in T175 flasks 
(Sarstedt). 
 
On the following day the supernatant in the flasks was carefully collected, after 
agitating the cell cultures to lift the sedimented non-adherent cells, and transferred 
into 50ml centrifugation tubes. Afterwards the cells were centrifuged for 8 minutes at 
1600 rpm. The resulting lymphocyte pellet was resuspended in 10 ml of TAIC culture 
medium and a cell-count was performed. CFSE labelled lymphocytes were co-
cultured with TAIC cells in six-well plates (Sarstedt) in a 2:1 ratio.    
 
2.2.2. Immunostaining for flow cytometry 
 
To analyse the lymphocyte subsets after TAIC co-culture the responder CFSE 
labelled lymphocytes were stained with directly-conjugated antibodies. Initially the co-
cultured cells were gently harvested with standard rubber cell scrapers (Sarstedt). 
The resulting cell solution in the six-well plates often contained aggregates of 
clustered cells. For this reason the solution was agitated with a pipette for several 
times. Then a volume of 300μl cell suspension was removed and transferred into 
cytometer tubes (Sarstedt) which were placed on ice. 30μl of 10% FcR blocking 
reagent (Miltenyi Biotec GmbH) was added to the tubes in order to reduce the 
unspecific antibody binding. After 30 minutes of incubation by room temperature, 
10μl of the respective antibodies (see table 2.1.) were added to the samples. The 
tubes received a strong vortex and a half hour of incubation in the dark at 4°C in the 
fridge followed. Before an absolute quantification of responder lymphocytes was 
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performed, the cells in the tubes were spiked with 5x106 CountBright beads 
(Invitrogen) and stained with 20μl of 7-aminoactinomycin (7-AAD; BD Biosciences, 
Heidelberg, Germany). 
 
Antibodies Cat. No 
CD4  
CD8  
CD3  
CD14  
CD19  
BD, 555349 
BD, 555367 
BD, 555339 
BD, 555399 
BD, 555413 
Table 2.1. List of used conjugated antibodies. Manufacture: BD Biosciences 
 
2.2.3. Flow cytometry analysis 
 
The samples were measured with a FACS Calibur flow cytometer (BD Biosciences) 
and the data analysis was performed with CellQuest software (BD Biosciences). The 
use of CFSE and several different antibodies allowed the measurement of the 
lymphocyte subsets of interest.  
 
2.3. Histology 
 
2.3.1. M reg cytology 
 
One day after the stimulation with IFN-γ the M-regs adopt their typical phenotype. In 
order to conserve the M reg cell structure and to fix them on microscope slides, the 
cells in the six well plates were gently washed three times with DPBS without Ca2+ 
and Mg2+ (Cambrex Bioscience). Further, 1ml of HyQ®TaseTM Cell Detachment 
Solution (Perbio Science GmbH, Bonn, Germany) was added to every well. In the 
following the cells were incubated by room temperature until the M regs apparently 
detached from cell culture plastic. The detached cells were transferred into 50ml 
tubes and centrifuged at 1000rpm for 8 minutes by room temperature. The resulting 
cell pellet was suspended into 8ml of 10% HABS macrophage medium and plated on 
microscope slide chambers (Lab-Tek II, Nunc, Germany). 
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2.4. Case study 
 
2.4.1. Ethics 
 
The administration of TAIC cells to a single patient in the reported case study was 
undertaken in accordance with all the relevant German laws. An independent local 
ethics committee approved the experimental set up for the described renal transplant 
recipient. The patient was informed in detail about possible risks and the procedure 
of the healing attempt before he gave his full, informed, written consent to it. The 
donor organ derived from the Eurotransplant pool and was transferred to the patient 
in conformity with the Eurotransplant and Bundesärztekammer allocation procedures. 
 
2.4.2. Generation of clinical grade TAIC cells 
 
TAIC cells for patients which received renal allografts from deceased donors were 
generated from splenic mononuclear cells. For this reason the donor spleen was 
recovered together with the transplanted kidney at the same time. Then the splenic 
capsule and the perisplenic adipose tissue were recovered before the spleen was 
subdivided into pieces of an approximately size of 1 cm3. These pieces were washed 
with DPBS without Ca2+ or Mg2+ (Cambrex Bioscience); subsequently a filtration of 
this suspension was performed to receive a relatively homogenous cell mixture.  
Afterwards 20ml of this cell suspension was layered onto 15ml of Ficoll (Biochrom 
AG) in 50ml centrifuge tubes (Becton Dickinson). The tubes went into the centrifuge 
at 400g for 20 minutes without brake by room temperature. The resulting leukocyte 
interface was removed carefully and transferred into a new 50ml centrifuge tube. A 
threefold wash in DPBS without Ca2+ and Mg2+ followed. 
 
The washed cells were suspended into normal TAIC culture medium at a density of 
5x107 cells/ml. A volume of 30 ml was added into T175 flaks (Sarstedt) which went 
directly into the incubator overnight at 37° C and 5% CO2. 
 
On the following day the supernatant cell fraction in the flasks were carefully 
extracted and transferred into new flasks. The adherent cells in the original flasks 
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obtained fresh TAIC medium, so that both the new and the original flasks were 
charged with a volume of 30 ml of TAIC culture medium. Subsequently all culture 
flasks returned back into the incubator. 
 
24 hours later a second transfer of the supernatant cells from those cultures which 
had been replated one day before was performed. This procedure guaranteed that as 
many as possible monocytes sedimented and adhered to culture plastic with the 
result that the best possible number of clinical feasible TAIC cells was produced. 
After the transfer the flasks were reincubated. 
 
On day 4 freshly prepared TAIC medium was supplemented with IFN-γ (R&D 
Systems) in a concentration of 25 ng/ml. Then the culture flasks were gently agitated 
and the old medium with all non-adherent cells was removed and discarded. 
Afterwards the resting cells in all flasks were put in culture with the IFN-γ 
supplemented TAIC medium. The cells went back into the incubator overnight. 
 
The harvest of the TAIC cells, which was performed on day 5, was done with great 
care by cell scraping. Initially the culture flasks were swung carefully before the 
medium was removed by pipetting. Following the adherent cells were washed with 
DPBS without Ca2+ and Mg2+; the cells were left for 10 minutes in DPBS before they 
were detached from the culture plastic with standard rubber cell scraper. To receive 
high cell viability TAIC cells were lifted with small gentle strokes which were 
performed very carefully. In the past it was shown in several trials that the use of 
trypsin as an alternative for detaching TAIC cells from the plastic bottom results in a 
reduced viability. In the end all TAIC cells were pooled together and suspended in an 
isotonic human albumin solution for central venous infusion.     
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3. Results 
 
3.1. Obtaining PBMC cells from LRS chambers 
 
3.1.1. General comments on leucocytes from LRS chambers 
 
Due to the fact that during our lab work we had several problems with the 
consignment of buffy coats, and in addition the cell quality of the isolated leucocytes 
was not satisfactorily, we decided to search for an alternative. It was discovered that 
during clinical platelet collection a spin-off product emerges that contains a high 
number of leucocytes. These leucocytes are collected in leucoreduction system 
chambers of apharesis instruments. In comparison to leucocytes from buffy coats 
these cells do not undergo numerous preparation steps which might have negative 
effects on cell morphology and function; instead the leucocytes from LRS chambers 
can be used directly after the separation process. In addition, the LRS chamber 
leucocytes derive from examined healthy patients because the criteria for admission 
are stricter than for normal blood donors. Since LRS chambers are conical in shape, 
we refer to then as “cones” for convenience.  
 
3.1.2. Significant numbers of PBMC cells with high viability can be  
                        isolated from LRS chambers 
 
To analyze if leucocytes from cones compare well in quality to those from buffy 
coats, six samples of cone leucocytes were verified in terms of cell quantity and 
viability. For this reason leucoreduction system chambers were drained and the 
resulting cell suspension was diluted into a final volume of 45ml DPBS without Ca2+ 
and Mg2+. The cells were then enumerated with an automated cell counter. 
The results illustrated in figure 3.1. are similar to those recovered from a good quality 
buffy coat. Further it was shown that lymphocyte and CD14+ monocyte viability was 
greater than 95% in donors 1-3.  
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 WBC RBC PLT LYM MON GRA 
Donor 1 7.32x10
8 
4.76x10
7 
1.33x10
10 
5.32x10
8 
8.40x10
7 
1.16x10
8 
Donor 2 7.52x10
8 
5.56x10
7 
1.43x10
10 
5.52x10
8 
1.00x10
8 
1.00x10
8 
Donor 3 5.92x10
8 
5.80x10
7 
1.05x10
10 
3.88x10
8 
7.60x10
7 
1.28x10
8 
Donor 4 1.23x10
9 
5.24x10
7 
1.22x10
10
 8.52x10
8
 1.08x10
8 
2.72x10
8 
Donor 5 6.16x10
8
 4.68x10
7 
1.03x10
10 
4.44x10
8 
6.40x10
7 
1.08x10
8 
Donor 6 7.96x10
8 
6.00x10
7 
7.84x10
9 
5.00x10
8
 1.00x10
8 
1.96x10
8 
Figure 3.1. Cell numbers of cone leucocytes derived from six different donors. 
Cell counts were performed with an automated cell counter. Cell numbers were 
expressed per ml. 
 
In order to prove the influence from leukocyte isolation process on cell viability and 
cell quantity, the number of cells after Ficoll density gradient centrifugation was 
analyzed with an automated cell counter.   
 
The leukocyte isolation process resulted in a considerable decrease of red blood 
cells and blood platelets. Likewise the cell numbers of leucocytes were reduced but 
not such extensive than those of erythrocytes and platelets [see figure 3.2]. This 
outcome was also observed in leukocyte isolation of buffy coats. The leukocyte 
separation did not influence the cell viability in a significant way.  
 
 WBC RBC PLT LYM MON GRA 
Donor 1 4.64x10
8 
<8.00x10
4 
6.00x10
8 
3.32x10
8 
4.00x10
7 
9.20x10
7 
Donor 2 4.60x10
8 
<8.00x10
4 
4.40x10
8 
3.48x10
8 
4.00x10
7 
7.20x10
7 
Donor 3 3.56x10
8 
<8.00x10
4 
4.40x10
8 
2.40x10
8 
4.00x10
7 
7.60x10
7 
Donor 4 6.60x10
8 
1.2x10
5 
1.08x10
9 
4.84x10
8 
6.00x10
7 
1.16x10
8 
Donor 5 3.12x10
8 
1.2x10
5 
7.60x10
8 
2.36x10
6
 2.80x10
7 
4.80x10
7 
Donor 6 4.68x10
8 
<8.00x10
4 
4.40x10
8
 3.08x10
6 
6.40x10
7 
9.60x10
7 
Figure 3.2. Cell numbers of cone leucocytes derived from six different donors 
after leucocyte isolation process. Cell counts were performed with an automated 
cell counter. Cell numbers were expressed per ml. 
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3.1.3. Mitogen stimulation assay 
 
Ascertaining in which intensity lymphocytes from cone origin react to PHA stimulation 
and in order to find out the mitogen concentration which leads to the strongest 
proliferation, lymphocytes were treated with different concentrations of PHA. The 
outcome was from interest because in several experiments before it was observed 
that at certain concentrations of PHA a cytotoxic effect occurred. 
 
Lymphocytes from three different donors were isolated and labelled with CFSE. 
CFSE staining is suited to demonstrate very clearly the several lymphocyte 
subpopulations which emerge as a consequence of the mitogen stimulation: With 
every cell division the CFSE signal halves its intensity and therefore it is possible to 
estimate the division index of various T cell subpopulations by flow cytometry. After 
the staining a number of 0,5x106 lymphocytes per well was seeded into 24-well 
plates. Further, the lymphocytes were divided into six trial groups; each group was 
stimulated with a different concentration of PHA (0μg/ml, 0,5μg/ml, 1μg/ml, 2μg/ml, 
4μg/ml and 8μg/ml).  
 
In both CD4+ and CD8+ lymphocytes from all donors were responsive to the 
administration of PHA, whereas the CD8+ fraction was more sensitive to the mitogen 
stimulation [see figure 3.3.]. The T cells responded to PHA stimulation in a dose-
dependent fashion with a near-maximal response at 2 µg/ml. Therefore and because 
of the assumption that higher concentrations of PHA might generate cytotoxic effects 
to some cell populations, the decision was made to use PHA in a concentration of 2 
µg/ml in the following mitogen experiments.    
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Figure 3.3. Mitogen stimulated proliferation within the CD4+ (A) and CD8+ (B) 
subset of cone-lymphocytes. Lymphocytes from three different donors were 
treated each with six different concentrations (0μg/ml, 0,5μg/ml, 1μg/ml, 2μg/ml, 
4μg/ml and 8μg/ml) of PHA. Division index was measured by flow cytometry.     
 
3.2. A description of the behaviour of allogeneic lymphocytes in TAIC co- 
culture 
 
3.2.1. Establishing a technique for quantifying lymphocytes by flow         
                      cytometry 
 
As described earlier, allogeneic mouse lymphocytes added into co-culture with IFN-γ 
treated MdCs disappear from the culture over time, which is thought to reflect an IFN-
γ-MdC-mediated cellular cytotoxicity (Brem-Exner et al., 2008). In order to analyse 
whether human TAIC cells feature similar T-cell eliminating abilities, and to develop 
an experimental system in which the molecular mechanism of any such effect could 
be studied, a flow cytometry-based technique for counting lymphocytes was 
established. Figure 3.4. illustrates the experimental model: TAIC cells were 
generated according to standard protocols, and then a determined number of 
allogeneic lymphocytes were added into the culture; at different time-points, the 
absolute number of remaining lymphocytes was counted. 
 
 
A B 
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Figure 3.4. An overview of the experimental design. Human TAIC cells were co-
cultured with CFSE-labelled allogeneic responder cells for 5 days and were then 
analysed by flow cytometry.  
 
It is not trivial to make an absolute quantification of the loss of lymphocytes from 
TAIC co-cultures. The absolute number of lymphocytes in the co-culture at any fixed 
time-point is determined by the initial number of lymphocytes, less those lost 
spontaneously, less those eliminated possibly by TAIC cells, plus any lymphocytes 
that arose by division in culture. Additionally this dynamic situation is complicated by 
the fact that the lymphocytes in co-culture are of two origins: those lymphocytes 
which are freshly added and those that remain as contaminants of the first phase of 
TAIC culture. Discriminating the residual and added lymphocytes is possible by flow 
cytometry using CFSE to label one or other population. 
 
Flow cytometry is a technique which has numerous advantages over alternatives 
methods for quantifying the number of lymphocytes in TAIC co-culture. Conventional 
cytotoxicity assays based on the release of radio label, particularly Chromium-51, 
from lysed responder cells are technically difficult and inherently hazardous. 
Cytotoxicity assays based on the release of cytosolic enzymes for instance G6PD do 
not differentiate between the death of responder cells, contaminating lymphocytes or 
0
Generation of TAIC Co-culture phase
10% HABS macrophage
medium or TAIC culture
medium
AB-Medium
+ IFN-γ
Adherent PBMC 
of donor origin
TAIC Flow cytometry:
Enumeration
Proliferation assay
CFSE-labelled
non-adherent
PBMC of 
recipient origin
1 2 3 4 5 6 7 8 9
Time (Days)
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even TAIC cells. The measurement by flow cytometry is made separately on each 
cell and does not present only a mean value for a whole population.  
 
Establishing the optimal labelling of responder lymphocytes for cell tracking and 
proliferation is a nontrivial procedure. The fact that the lymphocytes spent some time 
in co-culture before they are counted by flow cytometry makes it necessary to label 
them with a long term fluorescence like CFSE. But even CFSE staining loses 
intensity with the time and additionally by cell proliferation. Furthermore the intensity 
of the CFSE signal must be adapted to flow cytometry and even to the cells to be 
labelled because high doses of CFSE lead to cytotoxic effects. In order to find the 
accurate concentration several trials were undertaken. A concentration of 0,85 μg/ml 
incubated with 250x106 cells over 7 minutes at 37°C was found to be optimal. 
 
The ability of the flow cytometry to measure several cell-parameters at the same time 
allows it to determine the different lymphocyte subsets in the TAIC co-culture by 
adding monoclonal antibodies shortly before counting process. This procedure 
enables to analyze accurately the effect of TAIC cells to the lymphocyte subsets. In 
experiments unspecific binding was reduced by adding FcR Blocking reagent before 
the administration of antibodies occurred. Further antibodies for CD4 and CD8 afford 
a separation into three discretely identifiable groups of cells, namely CD4+, CD8+ and 
CD4- CD8-. Unfortunately both CD4 and CD8 are not completely cell-type specific so 
that for detailed characterizations for several cell populations accessorily CD3, CD14 
and CD19 antibodies were used. 
 
Due to the assumption that TAIC cells have the property to eliminate allogenic 
lymphocytes it was necessary to discriminate between living cells and dead cells. For 
this reason we worked with 7- aminoactinomycin (7-AAD), a DNA-binding dye which 
permeates apoptotic cells and which can be easily combined with fluorescent surface 
markers. 
 
Having statistical relevant means, samples were measured in triplicate and the 
standard deviation was defined, but there are still several sources of variation which 
have to be considered. To keep both TAIC and lymphocyte numbers exactly in same 
concentrations in every samples is unfeasible, impreciseness by pipetting and 
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counting are a remaining problem. Experiments were designed to minimize these 
effects by using flow cytometry as a highly specific and sensitive technique to 
determine the lymphocyte cell number at time-point zero which served as a relatively 
accurate reference. However, the absolute lymphocyte and TAIC number which was 
added per well in co-culture was calculated with a Coulter counter which possesses a 
considerable lesser accuracy of measurement than a flow cytometer. Accessorily the 
cell harvest is a source of variation because every harvest technique leads to a lost 
of cells which can diversify. In order to reduce the variation of cell lost, it was tried to 
harvest the cells in a standardized way. 
 
3.2.2. Co-culture of allogeneic lymphocytes with TAIC cells promotes    
                        lymphocyte survival 
 
In a first experiment, TAIC cells from three donors were prepared in six well plates 
according to the standard protocol; except that instead of TAIC medium, 10% HABS 
macrophage medium was used. On the final day of culture the TAIC cells were put 
into co-culture with freshly prepared CFSE labelled lymphocytes of two donors at 1:2 
ratio. Subsequently the number of allogeneic lymphocytes per well was analyzed and 
again 24 hours and 96 hours later. The data after 24 hours co-culture (data not 
shown) showed nearly no difference, the lymphocyte numbers both in TAIC co-
culture and control remained nearly stable. After 96 hours a considerable reduction of 
about 20% was observed. However in the lymphocyte control even a more 
intensively cell lost was noticed [see figure 3.5. A]. 
 
In a second experiment, the design remained the same as in the first experiment with 
the difference that the lymphocyte numbers were evaluated at 0 hours, 24 hours and 
210 hours. The absolute number of lymphocytes in co-culture was nearly unchanged 
after 24 hours (data not shown) as well as after 210 hours. By contrast the control 
lymphocytes were reduced by approximately the half [see figure 3.5. B]. These data 
illustrate exactly the opposite of what Brem-Exner and colleagues described in same 
experiments in mice. In these experiments it was demonstrated that mice TAIC cells 
effectively kill lymphocytes in co-culture (Brem-Exner et al., 2008). 
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Figure 3.5. Absolute quantification of CFSE+-Lymphocytes after co-culture with 
human TAIC cells of three different donors. Lymphocyte cell numbers are 
expressed as a percentage of the number of cells initially added to the cultures (red 
line). Cell counts were performed in triplicate. Values are shown are mean± standard 
error of the mean. LD= lymphocyte donor; C= control.  
 
3.2.3. An analysis of allogeneic lymphocytes in IFN-γ treated TAIC co-  
                        culture 
 
Further the effect of IFN-γ to the co-culture in the first and second experiment was 
studied. At the same day when TAIC cells and allogeneic lymphocytes were put in 
co-culture, 25 μg/ml IFN-γ was added to the cell suspension. In both experiments the 
treatment with IFN-γ did not show any relevant difference to the outcome we have 
seen in the IFN-γ untreated samples [see figure 3.6. A+B]. 
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Figure 3.6. Absolute quantification of CFSE+-Lymphocytes after co-culture with 
human TAIC cells of three different donors and supplementation of IFN-γ. 
Lymphocyte cell numbers are expressed as a percentage of the number of cells 
initially added to the cultures (red line). Cell counts were performed in triplicate. 
Values are shown are mean± standard error of the mean. LD= lymphocyte donor; C= 
control. 
 
3.2.4. Co-culture of PHA stimulated allogeneic lymphocytes with TAIC  
                        cells dampens lymphocyte proliferation 
 
To characterize in which way activated lymphocytes are affected by TAIC cells, the 
co-cultures were treated with PHA. The outcome of the first experiment revealed a 
considerable decrease both in co-culture and in the control, even the control 
lymphocytes declined more intensively [see figure 3.7. A]. This effect was already 
seen in experiments before (data not shown). An extensive augmentation of PHA-
treated lymphocytes was revealed in the second experiment both in the control and 
co-culture; notably the control-cells presented a massive proliferation whereas the 
lymphocyte-increase in co-culture comparatively was damped [see figure 3.7. B]. 
 
This suppressive effect also was detected in flow cytometry dot plots. 96 hours after 
PHA treatment the control lymphocytes in the first experiment presented a wide 
expanded population in which divers clearly separated lymphocyte clones were 
identifiable. However, in the PHA treated co-cultures as well a broadened population 
was observed in comparison to the PHA untreated samples, but the cluster was not 
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such wide as the control cluster and even it was difficult to differentiate several 
lymphocyte clons.        
 
 
Figure 3.7. Absolute quantification of CFSE+-Lymphocytes after co-culture with 
human TAIC cells of three different donors and supplementation of PHA. 
Lymphocyte cell numbers are expressed as a percentage of the number of cells 
initially added to the cultures (red line). Cell counts were performed in triplicate. 
Values are shown are mean± standard error of the mean. LD= lymphocyte donor; C= 
control. 
 
3.2.5. An analysis of the CD4+, CD8+ and CD4- CD8- subsets in PHA  
                        treated TAIC co-cultures  
 
In order to further dissect the suppressive effect on the T cell subsets in experiment 
two, the lymphocytes were labelled with monoclonal antibodies for CD4 and CD8 
shortly before flow cytometry measurement. The number of the CD4+ lymphocytes in 
co-culture and control did not shown significant differences [see figure 3.8. A] except 
that the CD4 fraction in the PHA stimulated control decreased compared to the co-
culture [see figure 3.9. A]. In comparison, there was a considerable increase of CD8+ 
lymphocytes in the control; up to five times more cells were detected than at time-
point 0 h. In contrast, the CD8+ fraction in co-culture did not expand and remained 
relatively stable [see figure 3.8. B +3.9. B]. The CD4- CD8- lymphocyte population did 
not show significantly changes between co-culture and control [see figure 3.8. C]. 
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Figure 3.8. Absolute quantification of different CFSE+-Lymphocyte subsets 
after co-culture with human TAIC cells and supplementation of PHA. CD4+ (A), 
CD8+ (B) and CD4-CD8- (C) Lymphocyte cell numbers are expressed as a 
percentage of the number of CD4+ (A), CD8+ (B) and CD4-CD8- (C) cells initially 
added to the cultures (red line). Cell counts were performed in triplicate. Values are 
shown are mean± standard error of the mean. LD= lymphocyte donor; C= control. 
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Figure 3.9. Percentage values of CD4+ (A) and CD8+ (B) CFSE+ Lymphocytes 
after co-culture with human TAIC cells and supplementation of PHA. CD4+ (A) 
and CD8+ (B) Lymphocyte numbers are expressed as a percentage of the total 
number of CFSE+ Lymphocytes. Cell counts were performed in triplicate. Values are 
shown are mean± standard error of the mean. LD= lymphocyte donor; C= control. 
 
3.2.6. Establishing an experiment with similar conditions as in the TAIC  
                        trials 
 
It is obvious that it is not possible to achieve same conditions in an in-vitro 
experiment as in a complex human organism. However in-vitro experiments depict a 
central role in clinical investigation and they are able to give us important information 
about potential modes of action and possible adverse effects.  
 
As allude in the introduction TAIC cells already were given to patients in the course 
of the TAIC-1 and TAIC-2 clinical studies as an adjunct immunosuppressive therapy 
(Hutchinson et al., 2008 a+b). The fact that a part of the trial participants were 
successfully weaned from an immunosuppressive triple therapy to a low doses 
monotherapy or even to a drug free period let us assume that TAIC cells have a 
significant immunosuppressive or even a potential tolerogenic effect. The results we 
have seen in the first experiments partly confirmed the assumption of a possible 
immunosuppressive effect. In order to specify this effect in more detail and to 
investigate the impacts of the cell preparation steps, which are inescapable for the 
generation of clinical grade TAIC cells, it was tried to set up an experiment which 
reflects similar conditions as in the TAIC 1 and 2 studies so far as possible [see 
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Figure 3.10.]. The main differences to the previous experiments were that different 
medium was used and that the TAIC cells were harvested before they were put in co-
culture with allogeneic lymphocytes. These two aspects might influence the outcome 
of an experiment considerably. In the past it was already shown that even a careful 
harvest with a cell scraper leads to immense cell destruction, so that a lot of dead cell 
debris is generated. It is to be assumed that such dead cell particles affect complex 
immunological processes with allogeneic lymphocytes. In addition the modification of 
the medium changes the microenvironment to which the TAIC cells are exposed and 
that might lead to phenotypically and functionally changes. 
 
 
Figure 3.10. An overview of the experimental design. Human TAIC cells were 
harvested before they were co-cultured with CFSE-labelled allogeneic responder 
cells for 5 days and were then analysed by flow cytometry.  
 
In a first experiment three different TAIC donors were combined with two different 
lymphocyte donors and in a second one two TAIC donors were put in co-culture with 
three lymphocyte donors; so that twelve different donor-recipient constellations were 
generated. 
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TAIC cells were produced like in the reported experiments except that the medium 
was adjusted to the medium which was used in the TAIC studies. Furthermore the 
source of cells was changed; instead of leucocytes from buffy coats, cone leucocytes 
were used. TAIC cells were harvested with a cell scraper, gently washed and then 
transferred into 6 well plates, in each well 2x106 cells. In parallel lymphocytes from 
donor different cones were isolated and further they were labelled with CFSE. Both 
TAIC cells and labelled lymphocytes were incubated overnight. On the following day 
2x106 CFSE+ lymphocytes were put in co-culture with the TAIC cells. 
 
Due to the fact that we have seen in the previous experiments a damped lymphocyte 
proliferation in PHA treated co-cultures and a survival effect in the untreated fraction, 
it was decided to divide the co-cultures into an untreated group and a PHA treated 
group, so that we can compare the outcome with the previous experiments. The cells 
were counted directly after the adding and once again 5 days later by FACS. The set 
up for the FACS-count and the harvest process remained the same as described in 
the previous experiments. 
 
3.2.7. Co-culture of allogeneic lymphocytes with “harvested” TAIC cells  
                        does not promote lymphocyte survival   
 
After five days of co-culture a cell lost of nearly 60% was revealed [see figure 3.11.]. 
Compared with the first experiments the cell death increased considerably but as 
also seen before the lymphocytes in monoculture showed a more extensive 
reduction. Nevertheless the difference between the co-culture data and the control 
data are nowhere near impressive then in the undertaken experiments before.    
 
3.2.8. Co-culture of PHA treated allogeneic lymphocytes with   
                      “harvested” TAIC cells affects lymphocyte proliferation 
 
In this experiment the addition of the mitogen PHA to the co-culture lead to a strong 
reduction of lymphocytes. Approximately 20% lymphocytes of recipient origin were 
detectable after the fifth day in the PHA treated co-cultures. The control showed 
approximately four times more lymphocytes after mitogen-stimulation [see figure 
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3.11.]. Such intensive effect was not seen in the experiments before. However in 
comparison to the previous undertaken long term experiment the proliferation effect 
induced by PHA was considerably weaker both in co-culture and in the control which 
might be caused by the different sources of lymphocytes and the shorter 
experimental time of five days. 
 
 
 
Figure 3.11. Absolute quantification of CFSE+-Lymphocytes after co-culture 
with human TAIC cells. The right two columns represent the PHA stimulated 
lymphocyte fractions whereas the lymphocytes represented in the left columns 
remained unstimulated. Lymphocyte cell numbers are expressed as a percentage of 
the number of cells initially added to the cultures (red line). Cell counts were 
performed in triplicate. Values are shown are mean± standard error of the mean. 
 
3.2.9. An analysis of the CD4+ and the CD8+ lymphocyte subsets in          
                           PHA treated “harvested” TAIC co-cultures 
 
Both the CD4+ and the CD8+ fraction in PHA treated TAIC co-culture were clearly 
hindered in their proliferation and reduced in their number. After five days of co-
culture only 20% of CD4+ and CD8+ lymphocytes were verifiable whereas in the 
controls approximately 100% CD4+ lymphocytes and about 120% CD8+ lymphocytes 
were detectable [see figure 3.12. A+B]. This TAIC mediated suppression effect of 
mitogen stimulated proliferation within the CD4+ and CD8+ lymphocyte populations is 
also mirrored nicely in the CFSE signal plots [see figure 3.13.]. The PHA treated 
control-lymphocytes represent clearly five till six subpopulations with different strong 
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CFSE signals as a consequence of cell division both in the CD4+ and the CD8+ 
fraction, whereas in TAIC co-culture the CFSE signal remained nearly unchanged. A 
damped lymphocyte proliferation in the previous experiments was only seen for the 
CD8+ lymphocyte fraction whereas the CD4+ subset remained unaffected.  
 
 
Figure 3.12. Absolute quantification of CD4+ (A) and CD8+ (B) CFSE+-
Lymphocytes after co-culture with human TAIC cells. The right columns 
represent the PHA stimulated lymphocyte fractions whereas the lymphocyte numbers 
represented in the left columns remained unstimulated. Lymphocyte cell numbers are 
expressed as a percentage of the number of CD4+ (A) and CD8+ (B) cells initially 
added to the cultures (red line). Cell counts were performed in triplicate. Values are 
shown are mean± standard error of the mean. 
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Figure 3.13. TAIC-mediated suppression of mitogen-stimulated proliferation 
within the CD4+ and CD8+ T cell subsets. The CFSE signal of lymphocytes was 
measured after the cells were cultured for five days in four different culture conditions 
by flow cytometry.  
 
3.3. TAIC cells of Donor Origin as a Novel Adjunct Immunosuppressive 
Therapy in Renal Transplantation – A Case Report 
 
Patient KW was a 36-year-old man who had an IgA Nephropathy, which was first 
diagnosed in year 1996. In March 2003, after he had been on haemodialysis for 
nearly three years, he received a deceased-donor kidney transplant. The donor 
kidney derived from a 57 year-old female with whom patient KW shared 5/6 HLA 
matches [see figure 3.15.]. The transplantation went without complications and the 
kidney was successfully engrafted with a warm ischaemia time of 30 min and a cold 
ischaemia time of 23 hours. After an initial dysfunction of the transplant during the 
first days after transplantation, the patient returned to theatre for a surgical treatment 
of a haematoma at the graft site.  
 
At first the patient was treated with a conventional immunosuppressive therapy 
comprising Tacrolimus (6mg p.o.), Rapamycin (3mg p.o.) and Prednisone (50mg 
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p.o.) which was then slowly reduced with the time [see figure 3.14. A]. TAIC cells 
were procured from the donor’s spleen, which was recovered at the same time as the 
donor kidney. A cell number of 1,07x106/kg bodyweight were prepared and was given 
to the patient by central venous infusion on the fifth day post-transplantation. The 
patient did not show any kind of acute complications because of the TAIC infusion. 
 
Due to the fact that the blood parameters only decreased slowly after the revision, 
with serum creatinine levels > 2,6 mg/dl, a transplant kidney biopsy was performed 
[see figure 3.14. C]. The biopsy showed a minimal acute tubular necrosis, a tubular 
microcalzification and a minor edema, leading to the diagnosis of tacrolimus toxicity. 
Thereupon the tacrolimus-dosis was reduced and a relevant decrease of his 
creatinine and his urea was detectable, such that, in the fifth week the patient’s 
creatinine-level was 1,56 mg/dl and the urea-level was 48 mg/dl. The levels remained 
stable over the following ten days, so that the decision was made to wean the patient 
from steroids over the following two weeks. A subsequent biopsy, 3 days after the 
steroid withdrawal, did not show any evidence for a rejection [see figure 3.14. D]. 
  
In the following two weeks, the graft function remained stable, so Rapamycin was 
also gradually phased out. In parallel, Tacrolimus was reduced with the time, such 
that serum levels were in the range of 5,0 to 7,0 ng/ml. The blood parameters were 
not affected by this reduction of immunosuppression. Two weeks later the weaning of 
tacrolimus was continued, the tacrolimus doses was changed from 0,5 mg/d BD to a 
0,5 mg/d OD, with the result that, at the end of the tenth week, the serum levels were 
below the detection threshold of clinical assay (< 4 ng/ml). 
 
At the end of the eleventh week, the patient’s creatinine level increased up to 2.76 
mg/dl and a maximal urea level of 89 mg/dl was measured. A biopsy taken at this 
time showed a medium-grade tubulitis with focal tubular atrophy and a high-grade 
interstitial lymphocyte infiltration [see figure 3.14. E]. This pathology conformed to a 
moderate focal rejection. The rejection episode was treated with a high dose of 
Decortin (100 mg/d) and 4 mg/d Tacrolimus. Under these conditions the creatinine 
and the urea-levels were reduced quickly and the graft function was restored at the 
end of the twelfth week. In the following weeks the graft function remained stable 
under prednisolone and tacrolimus.  
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The abrupt rise of creatinine and urea five weeks later were due to a uric-acid stone 
which resolved without surgical intervention. A few weeks later, a further biopsy was 
taken with the diagnosis of a low-grade rejection [see figure 3.14. F]. The biopsy 
showed a non-invasive, focal mononuclear cell infiltration and a minor focal fibrosis of 
the intertsitium; the glomeruli und the tubules appeared normal. Due to the fact that 
the time after the brief episode of renal failure caused by the uric-acid stone, the graft 
function was recovered and the creatinine and urea levels did not show any evidence 
of rejection, the decision was made not to increase the immunosuppressive therapy. 
In the past, such focal infiltrations of leucocytes were seen in several spontaneously 
tolerant kidney transplant recipients (Burlingham et al., 1999). 
 
During the 21st week, and up to the end of the first year posttransplantation, the 
patient received a tacrolimus monotherapy, so that his tacrolimus serum levels were 
kept in the range of 5.5 to 10 ng/ml. The following nearly four years the tacrolimus 
levels ranged between 3.1 to 8 ng/ml. Under these low-level immunosuppressive 
conditions the patient did not shown any evidence of rejection or other pathological 
processes. During this time-period his creatinine levels were consistenly between 1.7 
to 2.2 ng/ml. Presently, the patient is in a good condition and not impaired because of 
his transplant.  
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Figure 3.14. Summary of the clinical course of patient KW. (A) Patient KW 
received immunosuppressive therapy as illustrated. Four graft biopsies (B1-4) were 
taken at the time-points indicated. (B) Serum creatinine levels and trough serum 
tacrolimus levels. (C-F) PAS-stained sections from graft biopsies taken at week 2 (C), 
week 8 (D), week 11 (E) and week 17 (F): original magnification 200x. 
 Age Sex Race HLA Type CMV 
Recipient KW 36 male White 
caucasian 
A1 A3 B7 B8 BW6 BW6 CW7 
DR1 DR2 DR15 DR51 DQ1 DQ5 
DQ3 
negative 
Donor 57 female White 
caucasian 
A1 A3 B7 BW6 DR1 DR2 DR15 
DR51 DQ1 DQ5 DQ6 
negative 
Figure 3.15. Patient characteristics of donor and recipient KW. 
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4. Discussion 
 
4.1. PBMC cells from LRS chambers 
 
To receive significant and meaningful results in experimental assays it is of particular 
importance to work with reliably substances, this applies especially to experimental 
trials with viable human cells. The discovery of leucocytes which are a by-product of 
clinical platelet collection, provides an excellent source for cell experimental 
purposes. Their quick availability directly after donation and the minimal preparation 
steps for their isolation are the main advantages compared to conventional cell 
sources like buffy coats. We demonstrated that these conditions result in high cell 
quality and viability and therefore present ideal properties for cell culture 
experiments. Further, it was shown that CD4+ and CD8+ T cells from LRS chambers 
react intensively to mitogen stimulation in a dose-dependent manner, with a maximal 
response at approximately 8 μg/ml PHA. Due to the fact that we have seen cytotoxic 
effects of PHA to some cell subsets in previous experiments, we concluded that a 
concentration of 2 μg PHA per ml cell culture medium present an optimal lymphocyte 
proliferation stimulus. Nevertheless, the work with lymphocytes from cones also 
exhibit disadvantages in comparison to buffy coats: The usage of those cells is still 
limited because platelet collection with apharesis instruments is normally restricted to 
clinics with an associated institute for transfusion medicine and further the number of 
donors is considerably smaller than those for blood donors. In conclusion, PBMC 
from cones represent a very useful and good quality source for experimental 
purposes and therefore we preferred in our experiments lymphocytes from cone 
origin to those from buffy coats.  
 
4.2. TAIC co-culture with allogeneic lymphocytes 
 
Developing TAIC treatment as a clinical option for immunosuppressive therapy in 
transplantation medicine requires that the function of TAIC cells be better understood 
and the potential advantage of TAIC cells over conventional immunosuppressive 
therapies has to be demonstrated. 
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For more than twenty years, a wealth of very potent chemical and biological 
immunosuppressants was successfully used in order to prevent acute rejection 
episodes leading to about a 95% graft-survival one-year posttransplant. Though 
these immunosuppressive drugs became more and more selective for the defined 
subsets of immune cells, particularly for T cells, their non-specific way of 
immunosuppression and the involved consequences like higher risks for tumors and 
infections are still an unresolved problem. Furthermore these approaches have no 
bearing on the chronic rejection process and the assertion that acute rejection is a 
main factor leading to chronic rejection graft dysfunction, an often used argument for 
high doses immunosuppressive protocols, is now obsolete (Chatenoud, 2008). 
Therefore, it is obvious that alternatives are badly needed and that over the long-term 
the induction of tolerance is the goal which is to be achieved. Brem-Exner and 
colleagues engaged in this topic and detected immunosuppressive and anti-
inflammatory properties of TAIC cells in mice (Brem-Exner et al., 2008). Based on 
these results the effects of human TAIC cells to allogeneic lymphocytes were 
analyzed in this work.   
 
In the first experiments TAIC cells neither provoked a T cell depleting effect nor a 
strong proliferative response in co-cultured allogeneic T cells, but did promote 
allogeneic lymphocyte survival effect under the given conditions. This ability of TAIC 
cells was not seen in TAIC experiments before and is obviously caused by interaction 
between TAIC cells and allogeneic lymphocytes. In experiments in the past it was 
observed that single cultured cell subsets rely on stimuli from other cells to be 
rescued from death-by-neglect. Otherwise isolated cell subsets lose cell viability 
constantly over the time how it was observed in control lymphocytes which were not 
co-cultured with TAIC cells. In conclusion, an immunosuppressive effect of TAIC cells 
co-cultured with unstimulated allogeneic lymphocytes was not detectable. 
 
Munn et al. already described macrophages with T-cell suppressive properties 
among others the IDO-expressing subset of macrophages. For the induction of their 
immunosuppressive features CD40 ligation and IFN-y stimulation were essential 
(Munn et al., 1996; Munn et al., 1999). It is also assumed that IFN-γ plays a crucial 
role in the generation of human TAIC cells and further we speculated that the 
addition of IFN-γ to the co-culture might enhance the immunosuppressive properties 
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of TAIC cells. Contrary to expectation, the additional administration of IFN-γ did not 
influence the co-culture and the outcome was the same as we have seen it in co-
cultures without IFN-γ. 
 
Based on the previous results and the observation that mouse TAIC cells delete 
mitogen stimulated T cells more intensively (Brem-Exner et al., 2008) the idea has 
been evolved that human TAIC cells only exert suppressive properties to allogeneic 
lymphocytes when those are in an activated state. In order to demonstrate this, co-
cultures were treated with PHA. The depletion of lymphocytes after four days in both 
co-cultures and control cultures is presumably ascribed to the fact that PHA might 
affect cytotoxic to some lymphocytes. After a certain time, the addition of PHA 
resulted in a considerable suppression of stimulated allogeneic lymphocytes in TAIC 
co-culture. Interestingly, this damping effect initially was only seen in the CD8+ 
lymphocyte fraction. The recognized suppression could be caused by different 
mechanisms. One possibility might be that TAIC cells are capable to inhibit 
selectively the proliferation of activated CD8+ lymphocytes. This hypothesis is 
supported by the fact that nearly same cell numbers of CD8+ lymphocytes remained 
in co-culture with TAIC cells after PHA stimulation compared to the same 
lymphocytes co-cultured with TAIC cells alone. A further supporting point is that the 
flow cytometry dot plots depict clearly an impaired cell proliferation in the CD8+ 
lymphocyte fraction. Beyond the resulting CFSE- cell fraction in the co-cultures arose 
evidentially from CFSE+ lymphocytes as a consequence of mitogen stimulation. The 
fact that these cells are continuously positive stained for CD4 but not for CD8 is yet 
another argument for the assumption that under these specific conditions, given in 
the first experiments, TAIC cells selectively suppress the division of activated CD8+ 
lymphocytes. Nevertheless it is also possible that the observed suppressive effect 
might be caused by selective elimination of activated CD8+ lymphocytes or even 
might be a consequence of shortage of culture medium. These possibilities must be 
considered and therefore it is necessary that further studies dissect the detailed 
mechanism of the suppressive effect under these conditions. 
 
The preparation of the TAIC cells in the first two experiments did not mirror the 
circumstances under which clinical grade TAIC cells for the both TAIC-studies were 
prepared (Hutchinson et al., 2008 a+b). For this reason the experimental used 
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medium was adapted and most important the TAIC cells were exposed to the harvest 
procedure. These are two important points which might influence the outcome of an 
experiment considerably. Macrophages are sensitive responsive to their ambient 
microenvironment, therefore even little differences in the culture medium might result 
in phenotypically and functionally modifications (Stout et al., 2004). The cell harvest 
which was performed with conventional rubber cell scrapers leads demonstrable to 
an extensive loss of viable and functional TAIC cells. Hence, it is assumable that the 
immunosuppressive effect would be conspicuously mitigated in comparison to the 
results seen in the experiments before. We also have to consider a potential 
influence of the cell debris resulting during the TAIC cell harvest procedure. Probably 
such an influence is negligible in simplified in-vitro experiments but the administration 
of a large quantity of allogeneic cell debris into patients obviously represents a strong 
stimulus for the immune system. Therefore the treatment might accompany by 
sensitization of the recipient for donor alloantigens which can trigger an acute 
rejection episode or even a hyper acute rejection provided that TAIC cells are given 
prior to transplantation. Although so far no case of sensitization or pre-sensitization 
was observed, it must be aspired to develop a way of harvest without producing such 
high cell-damage. 
 
A further point which might affect the outcome in comparison to the preceding 
experiments is the usage of cone lymphocytes. As we demonstrated before the cell 
quality and viability are considerably higher compared to standard buffy coats which 
were used in the first experiments. The fact that we worked with the cone 
lymphocytes directly after their isolation from patients guaranteed that the cells were 
absolutely fresh. Hence, the work with such cells represents better the conditions 
how they would be due in vivo. 
 
The observation in the first experiments that TAIC cells lead to an allogeneic 
lymphocyte survival in co-culture compared to mono-cultured lymphocytes was not 
confirmed in the ensuing experiments. Though a reduced cell death in co-culture 
than in control cells was demonstrated, it was shown that TAIC cells were not able to 
rescue co-cultured allogeneic T cells from death-by-neglect. This finding might be 
related to the fact that the number of functional TAIC cells was reduced by cell-
scrapping. Also the usage of cone lymphocytes may contribute to that observation; 
 50 
 
this has to be assumed because even in monoculture the cell death clearly increased 
compared to the first experiments. However, the most interesting outcome of these 
experiments is the strong suppressive effect in mitogen stimulated co-cultures. Not 
only the intensity of suppression was extensively higher in comparison to previous 
results, but also TAIC cells suppress proliferation of both allogeneic CD4+ and CD8+ T 
cells in almost the same manner. Further it is concluded that the observed 
suppressive effect is caused by a selective elimination of activated T cells as fewer 
lymphocytes were detectable in PHA treated co-cultures than in untreated TAIC co-
cultures. As aforementioned T cell-suppressive features were already seen in IDO-
expressing subsets of macrophages and dexamethasone-treated macrophages and 
therefore these properties are not unique to TAIC cells (Munn et al., 1996; Munn et 
al. 1999). Anyhow, in connection with the quite remarkable results in the TAIC-2 
study (Hutchinson et al., 2008 a), the outcome of these experiments demonstrates a 
potential way of function of TAIC cells, namely that they specifically suppress 
activated T lymphocytes. 
    
4.3. Case report 
 
This case report describes the first attempt to treat a renal transplant patient with 
TAIC cells of donor origin. The application of TAIC cells via central venous infusion 
went without acute complications, including embolism, transfusion reactions, graft-
versus-host disease or infection. After a time period of almost five years, no signs of 
long-term adverse effects like malignancies arising from the transfused cells were 
detectable. Furthermore there was no evidence that the administration of TAIC cells 
leads to a sensitization to donor antigens or otherwise accelerates graft rejection. It is 
quite obvious that is not possible to draw relevant conclusions concerning possible 
adverse effects from a single case report but such single attempts are the basis for 
Phase-1 safety trials with a larger number of transplant recipients. Therefore the 
TAIC-1 and TAIC-2 study was performed, in which a number of 17 patients were 
treated with TAIC cells and in no case any evidence of acute side effects due to the 
cell application were registered (Hutchinson et al., 2008 a+b). 
 
 51 
 
In the TAIC-2 study it was shown that the pre-transplantation exposure to donor 
alloantigen in terms of TAIC cells allows an early withdrawal of conventional 
immunosuppression. Though, a complete reduction of immunosuppression was not 
tolerated. It is adopt that TAIC therapy with a suitable immunosuppressant weaning 
protocol might allow renal transplant patients to accept low-dose tacrolimus 
monotherapy, but without necessarily tolerating a complete withdrawal of 
immunosuppressive therapy. Hence, it is concluded that TAIC treatment is 
responsible for this state of donor-specific hyporesponsiveness (Hutchinson et al., 
2008a). Several previous attempts were undertaken to establish immunosuppressive 
protocols with and without adjunct tolerance-promoting therapies to maintain renal 
transplant patients on low-dose tacrolimus monotherapy (Bäckman et al.,2006; 
Coupes et al.,2002; Krämer et al.,2005; Shapiro et al., 2003; Starzl et al., 2003; Tan 
et al., 2005; Tan et al., 2006; Thomas et al, 2007). From these studies, it is clear that 
a substantial proportion of renal transplant recipients tolerated a low-dose 
monotherapy, although there is no way of predicting which patients might tolerate 
such a regime. 
 
Of course, this single case report can give us no information about the potential 
efficacy of TAIC treatment in the transplantation setting; particularly not when in 
previous studies transplant recipients successfully maintained on tacrolimus 
monotherapy without adjunct immune-conditioning therapy strategies. For this reason 
further clinical studies with larger numbers of participants will be necessary in order 
to asses the clinical benefit of TAIC treatment as an adjunct immunosuppressive 
therapy in renal transplantation. Beyond the lack of adequate control groups, 
because of ethical reasons in such trials, is a remaining problem and makes it difficult 
to draw firm conclusions. However, this case contains some intriguing features which 
deserve comment. Firstly, the graft biopsy taken at week 17 showed an unusual 
pattern of focal lymphocytic infiltration, which is nearly consistent with the histological 
appearance in two spontaneously tolerant renal transplant recipients with good graft 
function described by Burlingham and colleagues (Burlingham et al., 1999). In both 
cases biopsies shown small focal mononuclear cell infiltrates mainly consisting of 
CD4+ T cells. Further analysis demonstrated in the case of patient JB that the 
majority of the focal cells were from recipient origin surrounding a donor-derived cell. 
The CD4+ T-cell infiltrate contained a high proportion of anti-donor specific T-cell 
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clones. Therefore it was assumed that the presence of the donor cell might have 
immune regulatory properties. This adoption was additionally confirmed by studies of 
focal infiltrates which were seen in long-surviving rhesus monkeys with well-
functioning kidney allografts (Kirk et al., 1997; Knechtle et al., 1997). The focal 
interstitial infiltrates were characterized by aggregates of CD4+ T-cells arranged 
around a central antigen-presenting cell. For these reasons the described 
mononuclear cell infiltrates of the presented patient has to be analyzed in more detail 
with special focus on the origin of the cells and further detection for regulatory T cells 
would be from great interest. 
 
5. Abstract 
 
Clinical organ transplantation became the therapy of choice for endstage organ 
diseases. This development was closed related to the history of potent 
immunosuppressive drugs. Although major progress in the improvement of 
immunosuppressive therapy regimes was made, long-term graft survival is still limited 
and recipients are affected due to several adverse effects. For this reason numerous 
attempts were undertaken to induce operational tolerance. This thesis engaged in an 
attempt in which a subset of monocytes, named Transplant Acceptance Inducing 
Cells (TAIC), is given to patients in order to substitute conventional 
immunosuppressive therapy. The focus of the thesis was the detection of potential 
immunosuppressive effects to allogeneic lymphocytes induced by TAIC cells in in-
vitro co-cultures. Further a case study was performed to demonstrate an interesting 
outcome of a renal transplant patient who received TAIC cells and to show the 
clinical feasibility of this treatment. 
 
First experiments indicated that TAIC cells are able to suppress the proliferation of 
allogeneic CD8+ T cells under co-culture conditions, provided that the T cells are 
existent in a mitogen activated state. Without the addition of mitogen to co-cultures, 
TAIC cells promoted the survival of allogeneic lymphocytes. Under changed 
conditions, which were closer related to previous undertaken clinical TAIC trials, 
TAIC cells suppressed both CD4+ and CD8+ mitogen stimulated allogeneic 
lymphocytes. In absence of mitogen stimulation TAIC cells were not able to rescue 
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allogeneic lymphocytes from death by neglect. Although these results apparently 
demonstrate immunosuppressive properties of TAIC cells adverse activated 
allogeneic lymphocytes, it is obligatory to identify the exact mode of function of these 
cells in order to distinguish them clearly from other macrophage subsets with 
immunoregulatory features. 
 
The described renal transplant patient in the case study received TAIC cells 
afterwards the transplantation as an adjunct immunosuppressive therapy within an 
alternative healing attempt. The infusion of TAIC cells proceeded without any 
complications and the subsequent reduction of immunosuppressants up to a low 
grade tacrolimus monotherapy was well tolerated by the patient for the almost last 
five years. A biopsy, which was taken in the 17th week after transplantation, showed 
an unusual pattern of focal lymphocytic infiltration how it was already seen in 
spontaneously tolerant kidney transplant patients.  
 
Both the undertaken experiments and the described case study in this thesis 
demonstrate that TAIC cells have immunosuppressive characteristics which might 
have the potential to become a feasible immunosuppressive therapy approach in the 
clinic. But therefore it is necessary that further studies depict the specific mode of 
function of those cells and that meaningful clinical trials definitely prove the beneficial 
effect of TAIC cells in transplant patient. Furthermore it is needed that long-term 
experiments exclude potential adverse effects.          
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6.2. Abbreviation list 
 
APC, antigen presenting cell 
ATRA, all-trans-retinoic acid 
BD, blood dose 
°C, degree Celsius 
CD, cluster of differentiation 
CFSE, carboxyfluorescein succinimidyl 
            ester 
CFU, colony forming unit 
ClCR, creatinine clearance  
cm2, square centimetre 
CMP, common myeloid progenitor 
CMV, cytomegalovirus 
CSF, colony stimulating factor 
DC, dentritic cell 
dl, decilitre 
DPBS, Dubelcco`s phosphate-buffered 
            saline 
DSS, dextran sulphate sodium 
ESC, embryonic stem cell 
FACS, fluorescence activated cell    
            sorting 
FcR, Fc receptor (e.g. FcγRI) 
FITC, fluorescein isothiocyanate 
FOXP3, forkhead box P3 
g, gram 
GM-CFU, granulocyte-monocyte CFU 
GMP, good manufacturing practice 
GRA, granulocytes 
G6PD, glucose-6-phosphate  
            dehydrogenase 
HABS, human AB serum 
HEPES, N-2-hydroxyethylpiperazine     
         N´-2 ethanesulfonic acid 
HLA, human histocompatibility  
          leukocyte  antigen  
IDO, indoleamine 2,3-dioxygenase 
IFN-γ, interferon gamma 
Ig, immunoglobulin 
IL-, interleukin 
LPS, lipopolysaccharide 
LRS, leucocyte reduction system 
LYM, lymphocytes 
MACS, magnetic cell sorting 
M-CFU, monocyte CFU 
M-CSF, macrophage CSF 
MdCs, monocyte-derived cells 
mg, milligram 
MHC, major histocompatibilty complex 
ml, mililiter 
mM, milimolar 
MON, monocytes 
M reg, regulatory macrophage 
μg, microgram 
μl, microliter 
μm, micrometer 
n, sample size 
ng, nanogram 
ns, non-significant 
OD, oral dose 
PAF, platelet-activating factor 
PBMC, peripheral blood mononuclear  
             cell 
PE, phycoerythrin 
PHA, phytohemagglutinin 
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PLT, platelets  
p.o., per os 
RBC, red blood cells 
rpm, revolutions per minute 
TAIC, Transplant Acceptance Inducing  
           Cell 
TCR, T cell receptor 
TLR, Toll-like receptor 
TNF, tumor necrosis factor 
T reg, regulatory T cell 
U, unit 
WBC, white blood cells 
7-AAD, 7-Amino-actinomycin D 
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